← Leaderboards
Yohei Doi
University Of Pittsburgh At Pittsburgh
$5,766,320
Attributed
$6,947,944
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $730.2K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,848,589 · 8
AHRQ$99,355 · 1
By mechanism
R01$4,226,010 · 1
R21$2,186,833 · 5
K22$268,520 · 1
R03$266,581 · 2
Top collaborators
- Robert K Ernst5 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Fernanda P. Silveira$4,141,926
- Anuradha Ray$26,369,891
- Lee H. Harrison$19,820,888
- J Scott Vanepps$3,068,410
- Alexander Sundermann$128,655
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceAntibioticsInfectionResistance MechanismPathogenHospitalsLaboratoriesClinically RelevantResistant StrainAcinetobacter BaumanniiIn VitroColistinLipid AMembraneModificationOrganismPredispositionInvestigationAntimicrobialMulti-Drug ResistanceIn VivoPneumoniaBaseCarbapenem Resistance
Grant awards (25)
Defining high-risk genomic groups of Stenotrophomonas maltophilia$481,214
R21 · FY2025 · AI · contact PI
Colistin resistance in extensively drug-resistant Gram-negative pathogens$468,483
R01 · FY2024 · AI · contact PI
Colistin resistance in extensively drug-resistant Gram-negative pathogens$468,483
R01 · FY2023 · AI · contact PI
Colistin resistance in extensively drug-resistant Gram-negative pathogens$467,659
R01 · FY2022 · AI · contact PI
Colistin resistance in extensively drug-resistant Gram-negative pathogens$465,187
R01 · FY2021 · AI · contact PI
Mechanisms of cefiderocol resistance$183,500
R21 · FY2021 · AI · contact PI
Colistin resistance in extensively drug-resistant Gram-negative pathogens$493,437
R01 · FY2020 · AI · contact PI
Mechanisms of cefiderocol resistance$236,750
R21 · FY2020 · AI · contact PI
Study Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP)$198,865
R21 · FY2019 · AI · contact PI
Colistin-resistant Acinetobacter baumannii$371,203
R01 · FY2018 · AI · contact PI
Study Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP)$261,212
R21 · FY2018 · AI · contact PI
Colistin-resistant Acinetobacter baumannii$379,060
R01 · FY2017 · AI · contact PI
Mechanisms and implications of fosfomycin resistance in Escherichia coli$191,000
R21 · FY2017 · AI · contact PI
Colistin-resistant Acinetobacter baumannii$376,778
R01 · FY2016 · AI · contact PI
Mechanisms and implications of fosfomycin resistance in Escherichia coli$225,600
R21 · FY2016 · AI · contact PI
Colistin-resistant Acinetobacter baumannii$360,881
R01 · FY2015 · AI · contact PI
Colistin-resistant Acinetobacter baumannii$374,839
R01 · FY2014 · AI · contact PI
Markers predicting response to therapy for KPC-producing Klebsiella pneumoniae$189,650
R21 · FY2014 · AI · contact PI
Markers predicting response to therapy for KPC-producing Klebsiella pneumoniae$219,042
R21 · FY2013 · AI · contact PI
Optimizing Detection of MRSA Carriage$50,386
R03 · FY2013 · HS · contact PI
Optimizing Detection of MRSA Carriage$48,969
R03 · FY2012 · HS · contact PI
Multidrug-Resistant Acinetobacter baumannii$107,960
K22 · FY2010 · AI · contact PI
Epidemiology of Community-Associated, ESBL-Producing Escherichia coli$75,750
R03 · FY2010 · AI · contact PI
Multidrug-Resistant Acinetobacter baumannii$160,560
K22 · FY2009 · AI · contact PI
Epidemiology of Community-Associated, ESBL-Producing Escherichia coli$91,476
R03 · FY2009 · AI · contact PI